Abstract 4822
Background
Local advanced nasopharyngeal carcinoma (NPC) patients receiving neoadjuvant chemotherapy (NACT) and concurrent chemoradiotherapy (CCRT) suffered from malnutrition and declining quality of life. We investigate the impact of prophylactic or reactive nutritional support on nutritional status and quality of life.
Methods
Enrolled patients were randomly assigned to receive prophylactic (group A) or reactive nutrition intervention (group B). Group A was supported with enteral nutrition beyond daily diet from the beginning of radiotherapy (RT). Group B was treated with conventional diet guidance, appropriate nutritional intervention will be given when needed. Patients were asked to complete the EORTC QLQ-C30 and QLQ-H&N35 questionnaires at the baseline, before, during and after CCRT. Weight and hematological indexes were also collected. Statistical analyses are using SPSS 18.0.
Results
From October 2016 to May 2018, 114 patients were randomly assigned into the group A (n = 58) and B (n = 56). 80.7% of patients completed concurrent chemotherapy (A vs B = 90% vs 71%, P = 0.013, 95%IC=0.038-0.326). All patients experienced weight loss during the CCRT. Comparing to baseline, the rate of weight loss ≥5% before, during, at the end of RT and 1- and 3-month after RT were 3.5%, 28.9%, 29.8%, 64.7% and 33.2%. After treatment, Total serum protein and albumin of group A were better than B (68.7±6.31 vs 65.6±5.27 g/L, p = 0.003 and 41.86±4.05 vs 39.52±3.93 g/L, p = 0.001). Incidence of anemia at these times were 2%,37%,53%,55% and 19%. But no differences were found in two groups. Global health status scores in QLQ-C30 and QLQ-H&N35 decreased during NAT and CCRT. After RT, quality of life issues significant improved at the 1-and 3-months follow-up comparing to the end of treatment (65.34 and 76.4 vs 39.8, p = 0.00). But no statistical advantages of QoL were found in Patients in group A except feeling ill.
Conclusions
The nutrition status and QoL of NPC patients decreased during treatment. Though prophylactic nutritional intervention can enhance the completion of concurrent chemotherapy and keep the plasma protein stable, but it has no advantage in weight loss and quality of life except feeling ill.
Clinical trial identification
NCT02948699.
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Nutricia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract
2607 - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Presenter: Markus Hecht
Session: Poster Display session 3
Resources:
Abstract
1388 - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dillema finally resolved. An updated meta-analysis.
Presenter: Petar Suton
Session: Poster Display session 3
Resources:
Abstract
1478 - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.
Presenter: Majd Issa
Session: Poster Display session 3
Resources:
Abstract
3985 - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Presenter: Jovian Yu
Session: Poster Display session 3
Resources:
Abstract
4036 - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA
Presenter: Javier Martinez Trufero
Session: Poster Display session 3
Resources:
Abstract
4779 - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis
Presenter: Tony Richa
Session: Poster Display session 3
Resources:
Abstract
2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)
Presenter: Suraj Singh
Session: Poster Display session 3
Resources:
Abstract
5559 - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
Presenter: Sanket Shukla
Session: Poster Display session 3
Resources:
Abstract
3263 - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin
Presenter: Thana Patimarattananan
Session: Poster Display session 3
Resources:
Abstract